FDA grants a Breakthrough Device Designation for Spiderwort Spinal Cord Technology

Ontario Industry Updates
Written By Maura Campbell
Spiderwort_logo.png

Spiderwort Inc., a Canadian medical device company developing innovative biomaterials for regenerative medicine, is pleased to announce that the U.S. Food and Drug Administration (FDA) has designated CelluBridgeTM, Spiderwort’s Spinal Cord Scaffold Implant, as a “Breakthrough Device”.

Maura Campbell
Previous

ToeFX and Braze Mobility each receive $10,000 grant from BMO
Next

Intellijoint Surgical Ranks Number 1 on Deloitte’s Technology Fast 50™ Companies List